Skip to main content

Glycemic Variability Versus Average Glycemic Control: A Prospective Cohort Protocol Using Continuous Glucose Monitoring to Investigate Early Implant Healing in Type 2 Diabetes

Paper type
Prospective clinical research protocol (observational cohort)
Status
Original Work · Working Paper
Contents
  1. 1Introduction
  2. 2Background and Current Scientific Evidence
  3. 3Research Gap
  4. 4Research Objective and Central Hypothesis
  5. 5Scientific and Theoretical Framework
  6. 6Methodology
  7. 7Analytical Development
  8. 8Discussion
  9. 9Clinical Significance
  10. 10Limitations
  11. 11Future Validation
  12. 12Conclusion

Abstract

Background. Guidance on implant therapy in diabetes is framed in terms of HbA1c. The evidence is inconsistent: poorly controlled diabetes is associated with impaired osseointegration and more peri-implantitis in some reviews, while implant failure rates do not differ in meta-analysis and one-year survival has been high even at elevated HbA1c. HbA1c reports mean glycemia over months and is blind to glucose excursions. Experimental and clinical work outside dentistry links glucose fluctuation to oxidative stress, endothelial dysfunction, low bone turnover, and postoperative infection. A PubMed search combining continuous glucose monitoring or glycemic variability with dental implants or osseointegration returned no relevant study.

Objective. To specify a prospective cohort that tests whether glycemic variability during the healing period is associated with early implant stability and marginal bone change independently of HbA1c.

Design. Adults with type 2 diabetes receiving implants at healed sites wear a blinded continuous glucose monitor for three 14-day windows spanning placement, week 6, and week 12. Implant stability is measured by resonance frequency analysis at placement and at weeks 2, 4, 8, and 12; marginal bone level at loading and 12 months. Exposures are the coefficient of variation of glucose, mean amplitude of glycemic excursions, and times in, above, and below range. Covariates include HbA1c, mean sensor glucose, medication class, perioperative corticosteroid use, smoking, periodontal history, and bone quality.

Analysis. Mixed-effects models of the stability trajectory test whether variability metrics modify the depth and duration of the early stability decline after adjustment for mean glycemia. A late monitoring window serves as a negative-control exposure.

Central hypothesis. Higher glucose variability during the first 12 weeks is associated with a deeper and longer early decline in implant stability, independent of HbA1c.

Conclusions. The question appears unexamined. The protocol is designed to yield an interpretable answer whether the association exists or not. No data are reported.

Keywords: diabetes mellitus; continuous glucose monitoring; glycemic variability; HbA1c; dental implants; osseointegration; implant stability; time in range

1. Introduction

Clinicians who place implants in patients with diabetes are advised to consider glycemic control, and control is assessed by glycated hemoglobin. The advice rests on a body of evidence that is less clear than its routine application suggests. A systematic review concluded that patients with poorly controlled diabetes have impaired osseointegration, a higher risk of peri-implantitis, and more implant failure [1], and its update that poorly controlled diabetes is associated with more peri-implantitis while implant therapy remains safe with appropriate precautions [2]. An earlier review found that osseointegration succeeds under good metabolic control as it does without diabetes [3]. Yet a meta-analysis found no significant difference in implant failure between patients with and without diabetes (risk ratio 1.07) [4]. A meta-analysis restricted to studies with a defined case of peri-implantitis found the risk about 50% higher in diabetes [5], and a more recent one that well-controlled type 2 diabetes is not a risk indicator for peri-implant diseases while prediabetes and poor control are [6].

The prospective studies that measured early healing directly add nuance. Oates and colleagues followed implant stability by resonance frequency analysis over four months in patients whose HbA1c ranged from 4.7% to 12.6% and related poorer control to altered early stabilization [7]. In a larger study with baseline HbA1c up to 11.1%, one-year survival was high across the range, while early bone healing and stability were affected at higher HbA1c [8]. A trial that measured stability and bone markers in peri-implant fluid by glycemic control reached broadly similar conclusions [9], and immediate implants have been followed for two years across HbA1c strata [10]. The picture is of a healing process that is slowed, not prevented, by hyperglycemia, and of an HbA1c threshold that does not sharply separate success from failure.

HbA1c may simply be the wrong summary. It integrates glycemia over the lifespan of the red cell and translates into an estimated average glucose [11]. Two patients with the same HbA1c can differ widely in how that average is composed: one with stable glucose near the mean, another alternating between hypoglycemia and marked postprandial peaks. Continuous glucose monitoring (CGM) has made the difference measurable, and consensus statements now define standard metrics, among them the coefficient of variation of glucose and time in the target range [12–14].

There are mechanistic reasons to think the difference matters for a healing wound. Acute glucose fluctuations were more closely related to a marker of oxidative stress than sustained hyperglycemia in patients with type 2 diabetes [15]. Oscillating glucose impaired endothelial function and increased oxidative stress more than constant high glucose in clamp experiments [16], and intermittent high glucose enhanced apoptosis of endothelial cells in culture [17]. Bone formation at an implant depends on angiogenesis and on a timely transition from inflammation to repair, both vulnerable to oxidative and endothelial stress. In people with type 2 diabetes, the amplitude of glycemic excursions was negatively associated with bone turnover markers after adjustment for HbA1c [18]. After joint replacement and spinal fusion, higher postoperative glucose variability was associated with infection and other adverse outcomes [19–21].

Whether glucose variability during the weeks after implant placement relates to how the implant heals has not been studied, as far as a targeted search could determine (Appendix A). This protocol proposes to find out.

2. Background and Current Scientific Evidence

Diabetes and implant outcomes

The evidence was outlined above. Its inconsistencies have several sources. Studies differ in how diabetes and its control are defined and when HbA1c was measured relative to surgery. Patients with poor control are under-represented because clinicians defer treatment. Outcomes range from early stability to late peri-implantitis, which have different determinants. And HbA1c is a single number standing in for a metabolic state with several dimensions. A systematic review of diabetes and implant complications included only ten studies [22]. Reviews of osseous healing in diabetes emphasize impaired bone formation, altered inflammation, and microvascular changes [23, 24].

What HbA1c does and does not capture

HbA1c reflects mean glucose [11]. CGM-derived mean glucose can be converted to a glucose management indicator on the same scale [25]. Neither conveys dispersion. The principal CGM metrics of dispersion and exposure are the standard deviation and coefficient of variation (CV) of glucose; the mean amplitude of glycemic excursions (MAGE), which averages the excursions exceeding one standard deviation [26]; and the percentages of time in range (70–180 mg/dL), above range, and below range [13]. Variability has two dimensions, amplitude and time, and different metrics weight them differently [14]. Consensus recommendations specify a minimum duration and completeness of sensor wear for reliable estimates and propose targets for time in range and for CV; those targets should be taken from the consensus documents [12, 13] and are not restated here from memory.

Does variability matter beyond the mean? The general evidence

The evidence outside dentistry is mixed, and the disagreement is instructive. Supporting an independent role: the oxidative stress and endothelial studies cited above [15–17]; validation of time in range against microvascular outcomes in the Diabetes Control and Complications Trial data [27]; and the surgical cohorts [19–21]. Against it: an analysis of the same trial that examined within-day and between-day glucose variability from quarterly seven-point profiles in relation to microvascular complications [28], whose conclusions, as understood from the abstract, did not support a contribution of variability beyond mean glucose. That analysis used sparse capillary profiles in type 1 diabetes and chronic complications as outcomes; it does not speak directly to short-term healing in type 2 diabetes, but it is a caution against assuming that variability carries independent information.

Glycemic variability and bone

Diabetes increases fracture risk through mechanisms that include hyperglycemia, oxidative stress, and accumulation of advanced glycation end-products in bone matrix [29]. Studies using CGM have related variability metrics to bone outcomes in type 2 diabetes: higher variability with osteoporosis [30]; time in range with circulating osteocalcin [31]; and amplitude of excursions and dawn glucose rise with lower bone turnover markers, independent of HbA1c [18]. A recent review summarizes the relation between glucose fluctuation and diabetic osteoporosis and notes that it remains poorly understood [32]. These are cross-sectional associations with systemic bone status. None concerns local bone healing.

The oral–glycemic relationship runs in both directions

In mice monitored continuously, experimental periodontitis increased mean glucose, time above range, and glucose variability and induced insulin resistance [33]. Oral inflammation, surgical stress, perioperative corticosteroids, and the soft, often carbohydrate-rich diet that follows oral surgery can all be expected to perturb glucose. Variability measured in the healing period is therefore partly a consequence of the surgery and of any complications. An association between variability and poor healing could reflect the influence of healing on glucose. The design must address this directly.

Measuring early implant healing

Resonance frequency analysis provides a repeatable, non-invasive measure of implant stability as an implant stability quotient (ISQ) [34]. After placement, stability characteristically declines over the first weeks as primary mechanical stability is lost through remodeling, and then recovers as new bone forms. The depth and duration of this decline were the features that distinguished glycemic strata in earlier work [7]. They are continuous, sensitive, and obtainable at routine visits, which makes them suitable as primary outcomes for a study of early healing. They are surrogate measures. Their relation to long-term outcome is imperfect.

Summary

It is established that diabetes affects bone and wound healing, that HbA1c does not describe glucose variability, and that CGM does. Evidence that variability matters beyond mean glycemia is suggestive for oxidative stress, endothelial function, bone turnover, and surgical infection, and is contested for chronic microvascular complications. No study has examined variability in relation to implant healing.

3. Research Gap

The gap is simple to state. No study has measured glucose continuously around and after implant placement and related CGM-derived metrics to early healing. It is therefore unknown whether variability is associated with implant healing at all; whether any association is independent of mean glycemia; which metric, if any, carries the signal; and whether variability measured before surgery, which could guide timing and preparation, is as informative as variability measured during healing.

A registry search found no registered study of glycemic variability and dental implants and three records for continuous glucose monitoring with dental implants, none addressing healing in relation to variability (Appendix A).

4. Research Objective and Central Hypothesis

The primary objective is to estimate the association between glucose variability during the first 12 weeks after implant placement and the early trajectory of implant stability in adults with type 2 diabetes, independent of HbA1c and mean sensor glucose.

The central hypothesis is that a higher coefficient of variation of sensor glucose, averaged over the monitoring windows in the first 12 weeks, is associated with a larger maximum decline in ISQ from placement and a longer time to recover the placement value, after adjustment for HbA1c, mean sensor glucose, and prespecified covariates.

Secondary hypotheses: (a) time above range and MAGE show associations in the same direction; (b) time below range is examined separately and without a directional hypothesis; (c) variability in the preoperative portion of the first window is associated with the outcomes nearly as strongly as variability during healing, which would support its use in preoperative assessment; (d) variability is associated with early marginal bone change at 12 months; (e) variability measured in a late window, after healing, is not associated with the early stability decline once healing-period variability is accounted for.

The central hypothesis is refuted if the adjusted association is null with a confidence interval that excludes the prespecified minimum effect of interest.

5. Scientific and Theoretical Framework

Two exposures with different biology

Glycemic exposure of a healing site can be decomposed into a sustained component and a fluctuating component, which plausibly act through different pathways.

The sustained component is the time integral of glucose concentration. Non-enzymatic glycation of long-lived proteins, including bone collagen, proceeds in proportion to it, and it is what HbA1c measures. Its effects on matrix quality accrue over months [29].

The fluctuating component is the frequency and amplitude of excursions. Oxidative stress generation and endothelial dysfunction have been related to it specifically [15–17]. Its effects are acute and repeat with each excursion. A healing wound that depends on angiogenesis and on resolution of inflammation over days to weeks is exposed to hundreds of such excursions.

Hypoglycemic episodes form a third component, with counter-regulatory hormone release, and are common in tightly controlled patients on insulin or sulfonylureas. Time below range can be high when HbA1c is low.

The framework predicts that the fluctuating component relates more closely than the sustained component to outcomes that depend on vascular and inflammatory events in the first weeks, such as the stability trajectory, and that the sustained component relates more closely to outcomes dependent on matrix quality over the long term. It is offered as a rationale for the choice of exposures and outcomes. The study tests association; it does not test these mechanisms.

Causal structure and the reverse-direction problem

Variability during healing has determinants that precede surgery (the patient’s regimen, diet, and beta-cell reserve) and determinants that follow it (surgical stress, perioperative corticosteroids, analgesics, dietary change, infection). Only the first kind can be a cause of the surgical outcome in a sense useful for preoperative decisions. The second kind includes consequences of a difficult procedure or a complication, which also affect healing directly. Three design features address this. The first CGM window begins before surgery, so that preoperative variability is measured free of surgical effects. Perioperative exposures are recorded in detail. And the late window provides a negative-control exposure: if variability long after healing “predicts” the early stability decline as strongly as healing-period variability does, the association reflects a stable patient trait or confounding and not a time-specific effect.

6. Methodology

Design and setting

Prospective, multicenter observational cohort in periodontal, oral surgery, and prosthodontic clinics with access to diabetes care, reported to STROBE [35]. The protocol and analysis plan are registered before enrollment.

Participants

Inclusion. Adults with type 2 diabetes of at least one year’s duration; treatment plan including one or more implants in healed sites (at least 12 weeks after extraction) in the posterior mandible or maxilla; HbA1c within the range in which the treating clinician and physician judge elective surgery appropriate; stable glucose-lowering regimen for three months.

Exclusion. Type 1 diabetes; current personal use of unblinded CGM that the participant is unwilling to continue unchanged alongside the study sensor (such participants may be enrolled in a parallel stratum using their own device data); simultaneous major augmentation or sinus elevation at the index site; immediate loading; systemic corticosteroid therapy other than a single perioperative dose; bisphosphonate or other antiresorptive therapy; pregnancy; conditions invalidating HbA1c.

Index implant. One per participant, selected at random if several are placed, for the primary analysis.

Exposure measurement

Continuous glucose monitoring. A factory-calibrated sensor in blinded mode, so that neither participant nor clinician sees the data and behavior is unaltered. Three windows of 14 days: window 1 begins 7 days before surgery and ends 7 days after; window 2 is centered on week 6; window 3 on week 12. A fourth window at 6 months provides the negative-control exposure. A window is valid if sensor data cover at least the proportion of time recommended by consensus [12, 13].

Metrics. Computed for each window and for the average of windows 1 to 3 by standard definitions: mean sensor glucose and glucose management indicator [25]; standard deviation and coefficient of variation (CV = SD/mean), the primary exposure; MAGE [26]; percentage of time in range 70–180 mg/dL, above 180 mg/dL, above 250 mg/dL, below 70 mg/dL, and below 54 mg/dL [13]. The preoperative and postoperative halves of window 1 are also analyzed separately. Endpoint definitions for CV follow those used in registered CGM trials [36].

HbA1c. At enrollment (within four weeks before surgery) and at week 12, by a certified laboratory method.

Surgical and prosthetic protocol

Implant placement follows each center’s standard protocol with the following recorded: implant system, dimensions, and surface; bone quality by a standardized intraoperative classification and by planning-scan density; insertion torque; flap design; duration of surgery; antibiotic and corticosteroid administration with dose and timing; analgesics. Healing is non-submerged or with a healing abutment that permits repeated resonance frequency measurement without reopening. Loading is conventional, at or after week 12.

Outcomes

Primary. Two features of the ISQ trajectory at the index implant, measured at placement and at weeks 2, 4, 8, and 12 with the same device and transducer orientation by a trained examiner blinded to CGM data: the maximum decline from the placement value (ISQ at placement minus minimum ISQ), and the time at which ISQ regains the placement value, estimated from a smooth curve fitted to the five measurements [7, 34]. Measurements are made in duplicate in two directions and averaged.

Secondary. ISQ at week 12; change in marginal bone level from loading to 12 months on standardized radiographs read blind; soft-tissue healing index at weeks 1 and 2; postoperative infection or dehiscence; early failure (loss before loading); peri-implant crevicular fluid markers of inflammation and bone turnover at weeks 2 and 6 in a subset, as explored previously [9].

Covariates

Age; sex; diabetes duration; body mass index; glucose-lowering medication class (insulin, sulfonylurea, metformin, SGLT2 inhibitor, GLP-1 receptor agonist, thiazolidinedione, others), because classes differ both in their effect on variability and in their direct effects on bone; estimated glomerular filtration rate; smoking; history and current status of periodontitis; full-mouth plaque and bleeding scores; site (jaw, position); bone quality; insertion torque; implant dimensions; perioperative corticosteroid; center.

Sample size

The primary analysis tests whether CV explains variation in the maximum ISQ decline beyond a model containing HbA1c, mean sensor glucose, and about ten covariates. For a single tested predictor with a Cohen’s f^2 of 0.05, a small incremental effect chosen as the minimum of interest and not derived from prior data, 80% power, and two-sided α of 0.05, the required sample is approximately

n≈λ/(f^2)+k+1=7.85/0.05+12+1≈170  (1)

where λ=7.85 is the non-centrality parameter for one numerator degree of freedom at the stated power and α, and k the number of covariates. Allowing 15% for invalid sensor windows and loss to follow-up, 200 participants are to be enrolled. The calculation will be revisited after the first 40 participants using the observed variance of the outcome and the observed correlation between CV and mean glucose, without examining the exposure–outcome association.

Statistical analysis

Primary model. Linear regression of maximum ISQ decline on CV (averaged over windows 1 to 3) with adjustment for HbA1c, mean sensor glucose, and the prespecified covariates; center as a random effect. The same model for time to recovery, with appropriate handling of implants that have not recovered by week 12. The two primary outcomes are tested with control of the family-wise error rate.

Trajectory model. A mixed-effects model of all ISQ measurements with a flexible function of time and interactions between time and CV, to describe how the whole trajectory differs with variability.

Incremental information. Change in explained variance and likelihood-ratio tests when each variability metric is added to the model with HbA1c and mean glucose; the metrics are compared with one another using the same base model. Non-linearity is examined with restricted cubic splines [37].

Timing of exposure. Separate models use preoperative variability (first half of window 1), early postoperative variability (second half), and windows 2 and 3, to examine which period is most strongly associated.

Negative control. The 6-month window’s CV is entered alone and together with healing-period CV. Under a time-specific effect, healing-period CV retains its association and late CV does not.

Sensitivity. Exclusion of participants who received perioperative corticosteroids; exclusion of those with postoperative infection; stratification by insulin use; E-values for the primary estimate [38]; multiple imputation for missing covariates [39].

Interpretation rule. The minimum effect of interest is specified in advance as a difference in maximum ISQ decline, per standard deviation of CV, equal to one third of the between-participant standard deviation of the outcome. A confidence interval lying wholly within that margin is reported as evidence against a meaningful association.

Bias

Measurement. Blinded CGM prevents behavior change. ISQ examiners are blinded to glucose data. Sensor accuracy is lower in the hypoglycemic range and during the first day of wear; time below range is interpreted cautiously and the first 24 hours of each sensor are excluded.

Selection. Patients with very poor control are unlikely to be offered elective implants, which restricts the range of exposure and biases associations toward the null. The distribution of HbA1c and CV in the cohort is reported against population data.

Confounding. Addressed by the covariate set, the negative-control exposure, and the separate analysis of preoperative variability.

Ethics and safety

Institutional review board approval and written consent. Blinded CGM withholds real-time glucose data from participants, which is acceptable because it does not alter their usual care, but the protocol provides for unblinded review by the study physician if a participant reports symptoms of severe hypo- or hyperglycemia. Sensor data are reviewed after each window by an independent clinician for prespecified safety thresholds, and participants and their physicians are informed if these are crossed; such participants remain in the study, and the disclosure is recorded as a potential source of behavior change. Implant treatment proceeds according to standard care irrespective of study measurements.

7. Analytical Development

Why time in range is entangled with the mean and CV is less so

Approximate the distribution of sensor glucose within a window as normal with mean μ and standard deviation σ. Time above an upper limit U is then

TAR=1−Φ​((U−μ)/σ)  (2)

with Φ the standard normal distribution function. TAR, and its complement in time in range, depends on both μ and σ. For a patient with μ well below U, TAR is governed mainly by σ; for one with μ near or above U, mainly by μ. Across a cohort, time in range is therefore strongly correlated with mean glucose and HbA1c, and its association with an outcome cannot easily be attributed to variability. The coefficient of variation, σ/μ, is normalized by the mean and is less correlated with it, which is why it is the primary exposure. Glucose distributions are right-skewed, and equation (2) is an approximation used to make the structural point; the analysis uses the empirical metrics.

The practical consequence for analysis is collinearity. If CV and mean glucose are correlated at r, the variance of the estimated CV coefficient is inflated by 1/(1−r^2) relative to the uncorrelated case. At r=0.3, the inflation is 10%; at r=0.6, 56%. The interim check of this correlation in Section 6.7 exists to verify that the sample size remains adequate.

Reliability of a 14-day window and regression dilution

A 14-day window is a sample of a patient’s glycemic behavior over the healing period. If the between-patient variance of true CV is σ_b^2 and the within-patient, between-window variance is σ_w^2, the reliability of the mean of m windows is

R_m=(σ_b^2)/(σ_b^2+σ_w^2/m)  (3)

and an observed regression coefficient is attenuated to approximately R_m times its true value. With three windows, attenuation is modest if within-patient variation is smaller than between-patient variation and substantial otherwise. The study estimates σ_w^2 directly from the repeated windows, reports R_3, and gives a dilution-corrected estimate alongside the observed one. Had only a single window been used, a null result would be uninterpretable.

A simple exposure model distinguishing the two components

Let G(t) be glucose over a window of length W. The sustained exposure is the mean, G=W^(−1)∫_0^W G dt. A fluctuation exposure that weights excursions by their amplitude and frequency is the mean absolute rate of change,

Λ=1/W∫_0^W (dG/dt)dt  (4)

which equals twice the sum of excursion amplitudes per unit time. Λ rises both with larger and with more frequent excursions, whereas the standard deviation is insensitive to frequency: a slow drift and a rapid oscillation of the same amplitude have the same SD and very different Λ. If oxidative and endothelial stress respond to each excursion, as the clamp experiments suggest [16], Λ may be the more relevant quantity. It is computed from sensor data as an exploratory metric. Sensor noise inflates it, and the data are smoothed with a prespecified filter before differentiation.

What a null result would mean

Three explanations would be available for a null finding: no effect; an effect too small for the surrogate outcome to detect; or restriction of range, because patients with highly variable glucose were not offered implants. The design distinguishes them partially. The confidence interval bounds the effect size. The reliability analysis shows whether the exposure was measured adequately. And the reported distribution of CV shows whether the cohort included enough patients above the consensus target for variability to make the comparison meaningful. If few such patients are enrolled, the conclusion is limited to the range studied.

8. Discussion

The hypothesis has a clear rationale and little direct support. Its plausibility comes from oxidative stress and endothelial studies, from associations between variability and systemic bone turnover, and from surgical cohorts in which variability tracked infection. None of these is close enough to implant healing to predict the result, and the trial-based analysis that found no independent role for variability in microvascular complications [28] should temper expectations.

Several features of the question make a clean answer difficult. Variability and mean glycemia are correlated, both statistically and through shared causes such as insulin deficiency. Variability during healing is partly produced by the surgery. Patients with high variability are disproportionately those on insulin or sulfonylureas, with longer disease duration and more complications, each a plausible independent influence on healing. And the outcome is a surrogate. The protocol responds with preoperative measurement, a negative-control exposure, detailed covariates, and a prespecified minimum effect, but an observational design cannot remove confounding by disease severity. A positive finding would justify, and require, an interventional test.

Such a test is feasible in a way that is unusual for a risk factor. Variability is modifiable over weeks by structured use of unblinded CGM, medication adjustment, and dietary guidance. A randomized trial of a preoperative variability-reduction program against usual care, with stability trajectory as the outcome, would follow naturally. The observational study provides the effect-size estimate and the choice of metric on which such a trial would be planned.

The choice of ISQ trajectory as primary outcome can be criticized. Resonance frequency reflects the stiffness of the implant–bone system and is influenced by bone density, implant geometry, and the height of exposed implant; it is only moderately related to histological bone contact. Its merits here are sensitivity to early change, repeatability within implant, and precedent in exactly this population [7, 8]. Using each implant’s placement value as its own reference removes much of the between-site variation. Marginal bone change and early failure are included as outcomes closer to clinical relevance, with the recognition that the study is not powered for failure.

Hypoglycemia deserves separate comment. Patients with low HbA1c achieved through intensive therapy may spend appreciable time below range. If hypoglycemic episodes impair healing, the relation between HbA1c and outcome could be non-monotonic, and advice to lower HbA1c before surgery could in some patients be counterproductive. The study is not designed to test this, and it records the data needed to examine it.

Medication effects may confound or mediate. Some glucose-lowering classes affect bone metabolism directly, and classes differ in their effect on variability. The analysis adjusts for class, and the sample will be too small to estimate class-specific effects with confidence.

9. Clinical Significance

If variability is associated with early healing independently of HbA1c, preoperative assessment of patients with diabetes would have reason to include a period of glucose monitoring, and a patient with acceptable HbA1c and high variability would be recognized as potentially at higher risk than the HbA1c suggests. Conversely, a patient with moderately elevated HbA1c and stable glucose might be less at risk than assumed. Stabilizing glucose before elective implant surgery would become a testable preparatory step, in collaboration with the patient’s physician. With CGM increasingly used in type 2 diabetes, the data are often already available.

If no association is found within an adequately sampled range, HbA1c would be supported as a sufficient summary for implant planning, and attention could return to other determinants of healing in diabetes.

Until the study is done, the proposal does not justify altering how patients with diabetes are assessed for implants.

10. Limitations

The design is observational and cannot establish that variability causes impaired healing. The cohort will under-represent poorly controlled patients. The primary outcome is a surrogate. Fourteen-day windows sample glycemic behavior imperfectly. Blinded CGM cannot be enforced in patients who use their own sensors, who are analyzed separately. Sensor accuracy is limited at low glucose. Perioperative corticosteroids and diet alter variability and are recorded but not controlled. The sample-size calculation uses an assumed effect size. One index implant per patient discards information. Generalization to type 1 diabetes, to grafted or immediately loaded sites, and to long-term outcomes is not warranted. Consensus CGM targets and the conclusions of some cited studies were recalled or read from abstracts and must be confirmed against the full texts.

11. Future Validation

Replication in an independent cohort is the first requirement for any positive finding. A randomized trial of preoperative variability reduction would test causality. Extension to peri-implantitis would need long follow-up and repeated monitoring. Mechanistic substudies could measure oxidative stress markers and angiogenic factors in peri-implant fluid in relation to concurrent CGM data. If preoperative variability proves as informative as healing-period variability, a pragmatic study could evaluate a CGM-based preoperative checklist.

12. Conclusion

HbA1c has served as the measure of glycemic risk in implant dentistry without evidence that mean glycemia is the dimension of glucose exposure most relevant to healing. Glucose variability can now be measured unobtrusively, has plausible links to the vascular and inflammatory events on which early osseointegration depends, and has not been examined in this setting. The cohort described here would determine whether variability during healing relates to the early stability trajectory independently of HbA1c, with design features that address the influence of surgery on glucose and that make a null result interpretable. It reports no data.

Cite this paper

Jain S, Gupta A. Glycemic Variability Versus Average Glycemic Control: A Prospective Cohort Protocol Using Continuous Glucose Monitoring to Investigate Early Implant Healing in Type 2 Diabetes. Working paper. Center for Implant Dentistry; 2026. Available from: https://bayareaimplantdentistry.com/clinician-research-and-publications/glycemic-variability-implant-healing

References

  1. Naujokat H, Kunzendorf B, Wiltfang J. Dental implants and diabetes mellitus-a systematic review. Int J Implant Dent. 2016;2(1):5. doi:10.1186/s40729-016-0038-2 (opens in a new tab). PMID: 27747697 (opens in a new tab).
  2. Wagner J, Spille JH, Wiltfang J, Naujokat H. Systematic review on diabetes mellitus and dental implants: an update. Int J Implant Dent. 2022;8(1):1. doi:10.1186/s40729-021-00399-8 (opens in a new tab). PMID: 34978649 (opens in a new tab).
  3. Javed F, Romanos GE. Impact of diabetes mellitus and glycemic control on the osseointegration of dental implants: a systematic literature review. J Periodontol. 2009;80(11):1719-30. doi:10.1902/jop.2009.090283 (opens in a new tab). PMID: 19905942 (opens in a new tab).
  4. Chrcanovic BR, Albrektsson T, Wennerberg A. Diabetes and oral implant failure: a systematic review. J Dent Res. 2014;93(9):859-67. doi:10.1177/0022034514538820 (opens in a new tab). PMID: 24928096 (opens in a new tab).
  5. Monje A, Catena A, Borgnakke WS. Association between diabetes mellitus/hyperglycaemia and peri-implant diseases: Systematic review and meta-analysis. J Clin Periodontol. 2017;44(6):636-648. doi:10.1111/jcpe.12724 (opens in a new tab). PMID: 28346753 (opens in a new tab).
  6. Bencze B, Cavalcante BGN, Romandini M, Róna V, Váncsa S, Varga G, et al. Prediabetes and poorly controlled type-2 diabetes as risk indicators for peri-implant diseases:A systematic review and meta-analysis. J Dent. 2024;146:105094. doi:10.1016/j.jdent.2024.105094 (opens in a new tab). PMID: 38788918 (opens in a new tab).
  7. Oates TW, Dowell S, Robinson M, McMahan CA. Glycemic control and implant stabilization in type 2 diabetes mellitus. J Dent Res. 2009;88(4):367-71. doi:10.1177/0022034509334203 (opens in a new tab). PMID: 19407159 (opens in a new tab).
  8. Oates TW Jr, Galloway P, Alexander P, Vargas Green A, Huynh-Ba G, Feine J, et al. The effects of elevated hemoglobin A(1c) in patients with type 2 diabetes mellitus on dental implants: Survival and stability at one year. J Am Dent Assoc. 2014;145(12):1218-26. doi:10.14219/jada.2014.93 (opens in a new tab). PMID: 25429035 (opens in a new tab).
  9. Ghiraldini B, Conte A, Casarin RC, Casati MZ, Pimentel SP, Cirano FR, et al. Influence of Glycemic Control on Peri-Implant Bone Healing: 12-Month Outcomes of Local Release of Bone-Related Factors and Implant Stabilization in Type 2 Diabetics. Clin Implant Dent Relat Res. 2016;18(4):801-9. doi:10.1111/cid.12339 (opens in a new tab). PMID: 25825337 (opens in a new tab).
  10. Aguilar-Salvatierra A, Calvo-Guirado JL, González-Jaranay M, Moreu G, Delgado-Ruiz RA, Gómez-Moreno G. Peri-implant evaluation of immediately loaded implants placed in esthetic zone in patients with diabetes mellitus type 2: a two-year study. Clin Oral Implants Res. 2016;27(2):156-61. doi:10.1111/clr.12552 (opens in a new tab). PMID: 25623884 (opens in a new tab).
  11. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473-8. doi:10.2337/dc08-0545 (opens in a new tab). PMID: 18540046 (opens in a new tab).
  12. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, et al. International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care. 2017;40(12):1631-1640. doi:10.2337/dc17-1600 (opens in a new tab). PMID: 29162583 (opens in a new tab).
  13. Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi:10.2337/dci19-0028 (opens in a new tab). PMID: 31177185 (opens in a new tab).
  14. Kovatchev BP. Metrics for glycaemic control - from HbA(1c) to continuous glucose monitoring. Nat Rev Endocrinol. 2017;13(7):425-436. doi:10.1038/nrendo.2017.3 (opens in a new tab). PMID: 28304392 (opens in a new tab).
  15. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-7. doi:10.1001/jama.295.14.1681 (opens in a new tab). PMID: 16609090 (opens in a new tab).
  16. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57(5):1349-54. doi:10.2337/db08-0063 (opens in a new tab). PMID: 18299315 (opens in a new tab).
  17. Quagliaro L, Piconi L, Assaloni R, Martinelli L, Motz E, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003;52(11):2795-804. doi:10.2337/diabetes.52.11.2795 (opens in a new tab). PMID: 14578299 (opens in a new tab).
  18. Starup-Linde J, Lykkeboe S, Handberg A, Vestergaard P, Høyem P, Fleischer J, et al. Glucose variability and low bone turnover in people with type 2 diabetes. Bone. 2021;153:116159. doi:10.1016/j.bone.2021.116159 (opens in a new tab). PMID: 34461287 (opens in a new tab).
  19. Shohat N, Restrepo C, Allierezaie A, Tarabichi M, Goel R, Parvizi J. Increased Postoperative Glucose Variability Is Associated with Adverse Outcomes Following Total Joint Arthroplasty. J Bone Joint Surg Am. 2018;100(13):1110-1117. doi:10.2106/JBJS.17.00798 (opens in a new tab). PMID: 29975266 (opens in a new tab).
  20. Canseco JA, Chang M, Karamian BA, Nicholson K, Patel PD, Shenoy K, et al. Postoperative Glycemic Variability as a Predictor of Adverse Outcomes Following Lumbar Fusion. Spine (Phila Pa 1976). 2022;47(7):E304-E311. doi:10.1097/BRS.0000000000004214 (opens in a new tab). PMID: 34474452 (opens in a new tab).
  21. Patel PD, Canseco JA, Wilt Z, Okroj KT, Chang M, Reyes AA, et al. Postoperative Glycemic Variability and Adverse Outcomes After Posterior Cervical Fusion. J Am Acad Orthop Surg. 2021;29(13):580-588. doi:10.5435/JAAOS-D-20-00126 (opens in a new tab). PMID: 34135295 (opens in a new tab).
  22. Jiang X, Zhu Y, Liu Z, Tian Z, Zhu S. Association between diabetes and dental implant complications: a systematic review and meta-analysis. Acta Odontol Scand. 2021;79(1):9-18. doi:10.1080/00016357.2020.1761031 (opens in a new tab). PMID: 32401121 (opens in a new tab).
  23. Retzepi M, Donos N. The effect of diabetes mellitus on osseous healing. Clin Oral Implants Res. 2010;21(7):673-81. doi:10.1111/j.1600-0501.2010.01923.x (opens in a new tab). PMID: 20465554 (opens in a new tab).
  24. Jiao H, Xiao E, Graves DT. Diabetes and Its Effect on Bone and Fracture Healing. Curr Osteoporos Rep. 2015;13(5):327-35. doi:10.1007/s11914-015-0286-8 (opens in a new tab). PMID: 26254939 (opens in a new tab).
  25. Bergenstal RM, Beck RW, Close KL, Grunberger G, Sacks DB, Kowalski A, et al. Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring. Diabetes Care. 2018;41(11):2275-2280. doi:10.2337/dc18-1581 (opens in a new tab). PMID: 30224348 (opens in a new tab).
  26. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes. 1970;19(9):644-55. doi:10.2337/diab.19.9.644 (opens in a new tab). PMID: 5469118 (opens in a new tab).
  27. Beck RW, Bergenstal RM, Riddlesworth TD, Kollman C, Li Z, Brown AS, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019;42(3):400-405. doi:10.2337/dc18-1444 (opens in a new tab). PMID: 30352896 (opens in a new tab).
  28. Lachin JM, Bebu I, Bergenstal RM, Pop-Busui R, Service FJ, Zinman B, et al. Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial. Diabetes Care. 2017;40(6):777-783. doi:10.2337/dc16-2426 (opens in a new tab). PMID: 28404658 (opens in a new tab).
  29. Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL. Mechanisms of diabetes mellitus-induced bone fragility. Nat Rev Endocrinol. 2017;13(4):208-219. doi:10.1038/nrendo.2016.153 (opens in a new tab). PMID: 27658727 (opens in a new tab).
  30. Huang R, Wang H, Shen Z, Cai T, Zhou Y, Wang Y, et al. Increased Glycemic Variability Evaluated by Continuous Glucose Monitoring is Associated with Osteoporosis in Type 2 Diabetic Patients. Front Endocrinol (Lausanne). 2022;13:861131. doi:10.3389/fendo.2022.861131 (opens in a new tab). PMID: 35733774 (opens in a new tab).
  31. Liu J, Wei Y, Zang P, Wang W, Feng Z, Yuan Y, et al. Circulating osteocalcin is associated with time in range and other metrics assessed by continuous glucose monitoring in type 2 diabetes. Diabetol Metab Syndr. 2022;14(1):109. doi:10.1186/s13098-022-00863-4 (opens in a new tab). PMID: 35927761 (opens in a new tab).
  32. Chen F, Wang P, Dai F, Zhang Q, Ying R, Ai L, et al. Correlation Between Blood Glucose Fluctuations and Osteoporosis in Type 2 Diabetes Mellitus. Int J Endocrinol. 2025;2025:8889420. doi:10.1155/ije/8889420 (opens in a new tab). PMID: 39949568 (opens in a new tab).
  33. Kubota-Takamori M, Omori K, Kamei-Nagata C, Kiyama F, Ishii T, Nakayama M, et al. Continuous glucose monitoring reveals periodontitis-induced glucose variability, insulin resistance, and gut microbiota dysbiosis in mice. Sci Rep. 2025;15(1):34768. doi:10.1038/s41598-025-18594-7 (opens in a new tab). PMID: 41053144 (opens in a new tab).
  34. Sennerby L, Meredith N. Implant stability measurements using resonance frequency analysis: biological and biomechanical aspects and clinical implications. Periodontol 2000. 2008;47:51-66. doi:10.1111/j.1600-0757.2008.00267.x (opens in a new tab). PMID: 18412573 (opens in a new tab).
  35. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453-7. doi:10.1016/S0140-6736(07)61602-X (opens in a new tab). PMID: 18064739 (opens in a new tab).
  36. ClinicalTrials.gov. Identifier NCT03445065. Bethesda (MD): National Library of Medicine (US).
  37. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15(4):361-87. doi:10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 (opens in a new tab). PMID: 8668867 (opens in a new tab).
  38. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017;167(4):268-274. doi:10.7326/M16-2607 (opens in a new tab). PMID: 28693043 (opens in a new tab).
  39. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. doi:10.1136/bmj.b2393 (opens in a new tab). PMID: 19564179 (opens in a new tab).